Literature DB >> 12917242

Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

Sutep Jaruratanasirikul1, Somchai Sriwiriyajan.   

Abstract

OBJECTIVES: The aim of this study was to compare the pharmacokinetics and pharmacodynamics of meropenem when administered by 3 h infusion or bolus injection regimens. PATIENTS AND METHODS: The study was a randomized three-way crossover study with a 1 week wash-out period in 12 healthy volunteers. Each subject received a single dose of meropenem in three regimens: (i) bolus injection of 1 g meropenem; (ii) 3 h infusion of 1 g meropenem; and (iii) 3 h infusion of 0.5 g meropenem.
RESULTS: Following bolus injection of 1 g meropenem, the mean +/- s.d. percentages of the t > MIC of 4, 2 and 1 mg/L were 42.50 +/- 6.20%, 54.38 +/- 7.64% and 67.04 +/- 8.47% of an 8 h dosing interval, respectively. For the 3 h infusion of 1 g meropenem, the percentages of the t > MIC of 4, 2 and 1 mg/L were 59.27 +/- 7.34%, 71.97 +/- 8.63% and 86.07 +/- 9.41% of an 8 h dosing interval, respectively. For the 3 h infusion of 0.5 g meropenem, the percentages of the t > MIC of 4, 2 and 1 mg/L were 47.27 +/- 5.34%, 59.36 +/- 6.60% and 71.44 +/- 8.45% of an 8 h dosing interval, respectively.
CONCLUSIONS: We conclude that a 3 h infusion of 0.5 g or 1 g of meropenem both give greater values for t > MIC than a 1 g bolus and that intermittent infusion may be a useful mode of administration in tropical countries where drug instability may prevent the use of continuous infusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917242     DOI: 10.1093/jac/dkg378

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan; Jarurat Punyo
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions.

Authors:  Eiki Kikuchi; Junko Kikuchi; Yasuyuki Nasuhara; Satoshi Oizumi; Akitoshi Ishizaka; Masaharu Nishimura
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

4.  Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Authors:  Sutep Jaruratanasirikul; Suriyan Thengyai; Wibul Wongpoowarak; Thitima Wattanavijitkul; Kanyawisa Tangkitwanitjaroen; Waroonrat Sukarnjanaset; Monchana Jullangkoon; Maseetoh Samaeng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

6.  An investigation of the stability of meropenem in elastomeric infusion devices.

Authors:  Finbarr Foy; Giuseppe Luna; Jorge Martinez; Zach Nizich; Jason Seet; Katie Lie; Bruce Sunderland; Petra Czarniak
Journal:  Drug Des Devel Ther       Date:  2019-08-01       Impact factor: 4.162

7.  Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.

Authors:  Dariusz Onichimowski; Anita Będźkowska; Hubert Ziółkowski; Jerzy Jaroszewski; Michał Borys; Mirosław Czuczwar; Paweł Wiczling
Journal:  Pharmacol Rep       Date:  2020-04-16       Impact factor: 3.024

8.  Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia.

Authors:  Mona Ahmed Ammar; Waleed Abdalla
Journal:  Saudi J Anaesth       Date:  2018 Jan-Mar

9.  Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.

Authors:  Rodrigo A Sepúlveda; Patricio Downey; Dagoberto Soto; Kwok-Yin Wong; Yun-Chung Leung; Lok-Yan So; Max Andresen
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411

10.  Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease.

Authors:  Rezvan Hassanpour; Shadi Ziaie; Farzad Kobarfard; Mehran Kouchek; Mirmohammad Miri; Azadeh Ahmadi Koomleh; Seyedpouzhia Shojaei; Sara Salarian; Elham Pourheidar; Fatemeh Nezarat; Mohammad Sistanizad
Journal:  Eur J Clin Pharmacol       Date:  2021-01-06       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.